Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...
Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback